An exploration of the relationships between the effects of psilocybin on behavior, 5-HT 2A receptor occupancy, and neuroplastic effects in mice
Connor J. Maltby, Adam K. Klein, Enya Paschen, Jessica Pinto, Dino Dvořák, Joseph R. Hedde, Ashley N. Hanks, Massimiliano Bianchi, Zoe Hughes
Journal of Psychopharmacology January 6, 2026 DOI: 10.1177/02698811251395386 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Preclinical study Peer reviewed |
|---|---|
| Population | Mice |
| Intervention | Psilocybin |
| Dose | 1.5 mg/kg, 3 mg/kg |
| Duration | Behavioral testing 20-24 hours post-drug |
| Topics | Neuroplasticity Psilocybin Serotonin |
| Keywords | Prefrontal cortex Antidepressant Behavioural despair test Hallucinogen Glutamate receptor Anhedonia Pharmacology Hippocampus |
| Citations | 3 |
| Key points | Psilocybin produces dose-dependent 5-HT₂A receptor occupancy and region-specific neuroplastic changes in the prefrontal cortex, with distinct behavioral effects associated with anxiolytic-like and antidepressant-like properties. |
Abstract
Background: Psilocybin has shown rapid and sustained antidepressant effects in patients with major depressive disorder, yet the neurobiological mechanisms underlying these outcomes remain unclear.
Aims: This study aimed to bridge clinical and preclinical findings by investigating the relationships between 5-HT 2A receptor occupancy (RO) achieved after administration of psilocybin and its effects on behavior and markers of neuroplasticity in mice.
Methods: In vivo 5-HT 2A RO was determined via displacement of [ 3 H]MDL-100,907 in the prefrontal cortex (PFC). To relate RO with behavioral outcomes of psilocybin, we assessed the head twitch response (HTR) acutely and investigated behavior in the elevated zero maze (EZM) and forced swim test (FST) 20–24 hours post-drug. Neuroplastic changes were assessed by measuring α-tubulin post-translational modifications (PTMs) and expression of key synaptic proteins in both the PFC and amygdala.
Results: Psilocybin produced dose-dependent 5-HT 2A RO (RO₅₀ = 0.88 mg/kg) and an inverted-U dose–response in HTR, with peak effects occurring between ~44% and 62% RO. Behaviorally, a 1.5 mg/kg dose increased the open areas ratio in the EZM, while 3 mg/kg reduced immobility in the FST, 20 and 24 hours after dosing, respectively. Both dose levels shifted α-tubulin PTMs toward a more dynamic microtubule state and selectively increased synaptic marker expression in the PFC, not in the amygdala.
Conclusions: These findings suggest that the therapeutic effects of psilocybin could be mediated by dose- and region-specific enhancement of neuronal plasticity, with distinct signatures associated with anxiolytic-like and antidepressant-like properties.
Comparable studies
Other preclinical and animal studies on serotonin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo Mice | 2021 | Observational cohort | |
| Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Rats (implied by typical neurochemical study context) | 1987 | Experimental study | |
| Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors In vitro and in vivo (rodent) models | 2023 | Experimental study | |
| 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Rat brain | 1987 | Animal experiment | |
| Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs Human and mouse dopamine, norepinephrine, and serotonin transporters expressed in cells | 2006 | In vitro laboratory study |
Citations in the library
Cited by 5
- Acute psilocybin or ethocybin leads to a sustained increase in Pavlovian aversion memory in male mice Frontiers in Pharmacology September 22, 2026
- Current status and future prospects of research on psilocybin's regulation of neurotransmitters and their receptors related to the pathogenesis of tinnitus. Hearing research August 1, 2026
- Psilocybin selectively rescues cognitive flexibility impairments caused by aberrant prefrontal error signaling bioRxiv July 9, 2026
- α2-Adrenergic receptor modulates 5-HT2A-mediated behavioral effects of MDMA and psilocybin in mice. Molecular Psychiatry July 7, 2026
- Serotonin biology as a basis for explaining psychedelic drug action. Current Biology October 5, 2026
Cites 43
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Psychedelics Promote Structural and Functional Neural Plasticity Cell Reports June 1, 2018
and 38 more in the library